INTRODUCTION: Keratin (KRT) 24 is a cytoskeletal protein that plays a major role in the formation of intermediate filaments to provide mechanical stability. KRT24 overexpression facilitates tumour cell migration, invasion, and metastasis in several types of cancers. This study evaluates the clinicopathological significance of KRT24 expression in large breast cancer (BC) cohorts with long-term follow-up. METHODS: KRT24 mRNA expression was assessed in publicly available BC datasets (n = 13,025). KRT24 protein expression was evaluated immunohistochemically using well-characterised operable BC cohort (n = 832), and associations with clinicopathological features and patients' outcomes were evaluated. RESULTS: The KRT24 expression, at both transcriptomic and protein levels, was associated with features indicative of poor prognosis, including high histological grade, ER negativity, and HER2 positivity, and with poor patient outcomes. High KRT24 protein expression in chemotherapy-treated patients was significantly correlated with a shorter survival, a higher risk of distant metastases, and BC-related deaths. Additionally, patients with high KRT24 mRNA expression exhibited dysregulation of several differentially expressed genes and enriched pathways, including the cytokine-cytokine receptor interaction pathway, IL-17 signalling pathway, and oestrogen signalling pathway. CONCLUSION: KRT24 expression is associated with poor prognosis in BC. It also plays a predictive role in advanced BC and may represent a potential therapeutic target for patients with this aggressive disease.
Keratin 24 Predicts Poor Prognosis in Breast Cancer.
角蛋白24预示乳腺癌预后不良
阅读:5
作者:Kariri Yousif A, Alsaleem Mansour, Kariri Taher A, Alkharaiji Mohammed, Asad Mohammed, Rakha Emad A
| 期刊: | Pathobiology | 影响因子: | 2.000 |
| 时间: | 2025 | 起止号: | 2025 Apr 19 |
| doi: | 10.1159/000546022 | 研究方向: | 肿瘤 |
| 疾病类型: | 乳腺癌 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
